B-Engrossed
Senate Bill 711

Ordered by the House May 27
Including Senate Amendments dated April 15 and House Amendments
dated May 27

Sponsored by Senator PATTERSON; Senators FREDERICK, LIEBER, MANNING JR, Representatives ALONSO LEON, DEXTER, PRUSAK, SALINAS

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure.

Requires Department of Consumer and Business Services to study cost differences in hormone replacement drugs used by men and hormone replacement drugs used by women and report findings to Legislative Assembly no later than September 15, 2022. Requires department to keep strictly confidential information submitted in accordance with prescription drug price transparency program that is collected, used or relied upon for study, if information is not already in public domain and is confidential, proprietary or trade secret.


Takes effect on 91st day following adjournment sine die.

A BILL FOR AN ACT

Relating to gender disparities in cost of pharmaceuticals; and prescribing an effective date.

Whereas the cost of pharmaceuticals taken primarily by women is frequently more expensive than the cost of pharmaceuticals taken primarily by men; now, therefore,

Be It Enacted by the People of the State of Oregon:

SECTION 1. (1) The Department of Consumer and Business Services, as part of the prescription drug transparency program described in ORS 646A.689, shall conduct a study of disparities in the cost of hormone replacement drugs between those for men and those for women.

(2) The department shall report the findings of its study to the Legislative Assembly, in the manner provided in ORS 192.245, no later than September 15, 2022. The report shall include recommendations for legislative changes, if necessary, to address disparities in the costs of hormone replacement drugs based on sex.

(3) The department shall keep strictly confidential any information collected, used or relied upon for the study conducted under subsection (1) of this section if the information is:

(a) Information submitted in accordance with the requirements of the prescription drug price transparency program described in ORS 646A.689;

(b) Not already in the public domain; and

(c) Confidential, proprietary or a trade secret as defined in ORS 192.345.

SECTION 2. Section 1 of this 2021 Act is repealed on January 2, 2023.

SECTION 3. This 2021 Act takes effect on the 91st day after the date on which the 2021 regular session of the Eighty-first Legislative Assembly adjourns sine die.